Breaking AI & Tech News Analyzed

The courtroom showdown: Musk sues Altman over OpenAI’s missionOn Monday, April 27, 2026, a high‑profile lawsuit between two Silicon Valley titans began in a federal courthouse in Oakland, as Elon Musk alleges that Sam Altman betrayed the original non‑profit charter of OpenAI by converting it into a for‑profit entity.Trial kicks off in Oakland: accusations and stakesThe complaint names Altman, OpenAI president Greg Brockman, and major partner Microsoft for breach of contract and unjust enrichment. Jury selection starts Monday morning, with opening arguments expected later in the week. The trial is projected to run two to three weeks.Musk’s claims: breach of the 2015 founding agreement, removal of Altman and Brockman, reversal of the for‑profit restructuring.OpenAI’s defense: Musk consented in 2017 to a for‑profit step, his $38 m contribution was a tax‑deductible donation, not an equity investment.Key witnesses: Musk, Altman, Microsoft CEO Satya Nadella, among others.Financial stakes: $134 bn damages and a $1 tn valuationDamages sought: more than $134 bn, which Musk says would be funneled to OpenAI’s non‑profit arm.OpenAI’s market outlook: expected IPO later in 2026 at an estimated valuation of around $1 tn.Funding history: Musk contributed roughly $38 m in 2015‑2017; OpenAI has since raised tens of billions from Microsoft.Implications for AI governance and Silicon Valley power dynamicsThe case tests the enforceability of early‑stage non‑profit agreements once a venture scales into a multibillion‑dollar for‑profit. A ruling against Altman could force a structural unwind, jeopardizing the upcoming IPO and unsettling investor confidence in AI startups. It also spotlights the tension between visionary founders and capital‑heavy partners like Microsoft.What the verdict could mean for OpenAI’s IPO and the broader AI industryIf the court orders a reversal of the for‑profit conversion, OpenAI may have to restructure again, delaying or derailing its planned public listing. Conversely, a dismissal would reinforce the precedent that founders can pivot business models without retroactive liability, likely encouraging further large‑scale AI investments. Stakeholders are watching closely as the outcome could reshape governance norms for future AI ventures.

A federal judge has thrown out the majority of Blake Lively's claims against Justin Baldoni, her co-star and director of the domestic violence film It Ends With Us.In a court ruling on Thursday, Judge Lewis Liman dismissed 10 of the 13 claims in Lively's lawsuit against Baldoni, including claims of sexual harassment, conspiracy, and defamation. Only three claims will now be heard at trial: breach of contract, retaliation, and aiding and abetting in retaliation.The decision leaves Lively's case with a narrower focus, limited to her claims that Baldoni was behind a retaliatory campaign which shared and boosted negative stories about her online.“This case has always been and will remain focused on the devastating retaliation and the extraordinary steps the defendants took to destroy Blake Lively’s reputation because she stood up for safety on the set and that is the case that is going to trial,” Sigrid McCawley, an attorney for Lively, said in a statement.The case is set to go to trial in May after mediation failed last month.

New York City's public hospital system has announced that it will not be renewing its contract with Palantir, a data analytics and AI firm, amid growing controversy over its government contracts in the UK. The decision comes as health officials in the UK express concerns over data privacy issues related to Palantir's £330m agreement with the National Health Service (NHS).The contract between NYC Health + Hospitals and Palantir, which focused on recovering money for insurance claims, was set to expire in October. According to documents shared with the Guardian, Palantir has paid nearly $4m to the hospital system since November 2023. The contract allowed Palantir to review patient health notes and help the hospital claim more money in public benefits through programs like Medicaid.Despite assurances from NYC Health + Hospitals that there was an 'absolute firewall' preventing Palantir from sharing information with US Immigration and Customs Enforcement (ICE), activists and data privacy experts have raised concerns over the potential risks of Palantir accessing de-identified patient data for purposes other than research.As New York City prepares to part ways with Palantir, the company is expanding its influence in the UK, despite backlash from activists and lawmakers. Palantir has contracts with the British government's Ministry of Defence and is seeking access to sensitive national financial regulation data through a contract with the Financial Conduct Authority.Medact, a health justice charity, has raised concerns that Palantir's software could enable 'data-driven state abuses of power', including US-style ICE raids. In response, Palantir has denied that its data could be used in this way, citing that it would be illegal and a breach of contract.The decision by NYC Health + Hospitals to drop Palantir has been hailed as a victory by activists, who are now calling on the NHS to follow suit and terminate its £330m contract with the company. The 'Purge Palantir' campaign, which involves nurses, pro-Palestinian activists, and social and climate justice groups, aims to stop Palantir from contracting with government agencies, universities, and corporations.